InvestSMART

Pharmaxis Ltd (ASX: PXS) - Announcements

- Current share price for PXS : $0.027

ASX company news and announcements for Pharmaxis Ltd (PXS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pharmaxis Ltd (PXS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pharmaxis Ltd (PXS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pharmaxis Ltd (PXS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Boehringer Ingelheim Initiates Phase IIa Study in NASH 25 Aug 2017 8:18AM $0.270 $0.027 fallen by 90%
- Positive Recommendation for Broader Bronchitol Access in Aus 18 Aug 2017 4:29PM $0.270 $0.027 fallen by 90%
- Appendix 3B - Exercise of Employee Options 14 Aug 2017 8:35AM $0.265 $0.027 fallen by 89.81%
- Preliminary Final Report June 2017 11 Aug 2017 8:25AM $0.275 $0.027 fallen by 90.18%
- Investor Presentation 1 Aug 2017 10:12AM $0.265 $0.027 fallen by 89.81%
- Quarterly Shareholder Update - June 2017 28 Jul 2017 10:01AM $0.268 $0.027 fallen by 89.91%
- Appendix 4C - quarterly June 2017 28 Jul 2017 10:00AM $0.268 $0.027 fallen by 89.91%
- Presentation by CEO at Bioshares Biotech Summit 21 Jul 2017 8:31AM $0.255 $0.027 fallen by 89.41%
- Proposed Issue of Securities to Chief Executive Officer 18 Jul 2017 9:42AM $0.255 $0.027 fallen by 89.41%
- Appendix 3B - Employee Performance Rights and Shares - 2017 18 Jul 2017 9:39AM $0.255 $0.027 fallen by 89.41%
- Pharmaxis Investor Presentation 29 Jun 2017 8:28AM $0.245 $0.027 fallen by 88.98%
- Interview with Pharmaxis Chief Executive Officer 13 Jun 2017 10:09AM $0.265 $0.027 fallen by 89.81%
- Pharmaxis Announces Results of Pivotal CF Clinical Trial 13 Jun 2017 9:33AM $0.265 $0.027 fallen by 89.81%
- Initial Director's Interest Notice 7 Jun 2017 1:58PM $0.270 $0.027 fallen by 90%
- Director Appointment 7 Jun 2017 1:53PM $0.270 $0.027 fallen by 90%
- Investor Presentation 15 May 2017 8:24AM $0.260 $0.027 fallen by 89.62%
- Pharmaxis Set to Generate Further Euro 10m Milestone Payment 15 May 2017 8:24AM $0.260 $0.027 fallen by 89.62%
- Pharmaxis Appoints Chiesi as Bronchitol Distributor in Italy 8 May 2017 1:49PM $0.265 $0.027 fallen by 89.81%
- Appendix 4C - quarterly cash flow 18 Apr 2017 9:34AM $0.280 $0.027 fallen by 90.36%
- Quarterly Shareholder Update March 2017 18 Apr 2017 9:34AM $0.280 $0.027 fallen by 90.36%
- Change in substantial holding 5 Apr 2017 8:23AM $0.280 $0.027 fallen by 90.36%
- Change in substantial holding 4 Apr 2017 1:07PM $0.275 $0.027 fallen by 90.18%
- Change in substantial holding from AEF 3 Apr 2017 4:20PM $0.280 $0.027 fallen by 90.36%
- Change in substantial holding 31 Mar 2017 4:50PM $0.290 $0.027 fallen by 90.69%
- Change in substantial holding from AEF 30 Mar 2017 5:42PM $0.265 $0.027 fallen by 89.81%

476 - 500 of 836 results

Page 20 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.